barchart

MANNKIND CORP

FORM 8-K

(Current Report Filing)

Filed 03/26/24 for the Period Ending 03/25/24

Address 1 CASPER STREET, DANBURY, CT, 06810

Telephone (727) 384-2323

CIK 0000899460

Symbol MNKD

SIC Code 2834 - Pharmaceutical Preparations

Fiscal Year 12/31

Powered by **barchart**

https://www.barchart.com/solutions
© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

| | | CURRENT REPORT | |
|-----------|--|---|---|
| | Pursuant to Section | n 13 or 15(d) of the Securities E | exchange Act of 1934 |
| | Date of R | eport (Date of earliest event Reported): Ma | rch 25, 2024 |
| | (E | MannKind Corporation Exact Name of Registrant as Specified in Ch | arter) |
| (S | Delaware tate or Other Jurisdiction of Incorporation) | 000-50865 (Commission File Number) | 13-3607736 (I.R.S. Employer Identification Number) |
| | | Casper Street, Danbury, Connecticut 0 ddress of Principal Executive Offices) (Zip 0 | |
| | (Re | (818) 661-5000 gistrant's telephone number, including area | a code) |
| | (Forme | N/A name or former address, if changed since | last report) |
| | | Form 8-K filing is intended to simultaneous ovisions (see General Instruction A.2. of Fo | |
| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | |
| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | |
| | Pre-commencement commu | nications pursuant to Rule 14d-2(b) under t | the Exchange Act (17 CFR 240.14d-2(b)) |
| | Pre-commencement commu | nications pursuant to Rule 13e-4(c) under t | he Exchange Act (17 CFR 240.13e-4(c)) |
| | (17 CFR §230.405) or Rule 12b | gistrant is an emerging growth company as -2 of the Securities Exchange Act of 1934 (1 | |
| | r complying with any new or re | te by check mark if the registrant has elect evised financial accounting standards provi | |
| Securitie | s registered pursuant to Section | on 12(b) of the Act: | |
| | Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Comn | non Stock, par value \$0.01 per share | MNKD | The Nasdaq Stock Market LLC |

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)(c)

Effective April 22, 2024 (the "Effective Date"), Steven B. Binder is retiring as the Chief Financial Officer and principal accounting officer of MannKind Corporation (the "Company"). On March 25, 2024, the Company's board of directors appointed Christopher Prentiss as the Company's Chief Financial Officer and principal accounting officer, effective on April 22, 2024, succeeding Mr. Binder in these capacities. Commencing on the Effective Date, Mr. Binder's title will be changed to Executive Vice President, Special Projects, a role he is anticipated to serve in through December 31, 2024.

Mr. Prentiss, age 48, has served as Chief Financial Officer of ADARx Pharmaceuticals, Inc., a privately held clinical-stage biotechnology company, since September 2022. Between April 2015 and November 2021, he held a series of finance positions of increasing responsibility at the commercial-stage biotech company Adamas Pharmaceuticals, Inc. ("Adamas"), culminating in Chief Financial Officer commencing in November 2019. His responsibilities at Adamas included finance, accounting, investor relations, information technology and facilities. Prior to that, Mr. Prentiss was Senior Director, Controller at Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, from May 2012 to June 2013, where he was responsible for the accounting and tax functions. He previously served in senior finance positions of increasing responsibility during his earlier career at the Company between 2005-2012. Prior to that, Mr. Prentiss was a Senior Manager at KPMG LLP in the assurance practice. Mr. Prentiss received a Bachelor's of Science degree in Accounting from Loyola Marymount University, and a Masters of Business Administration from Indiana University. Mr. Prentiss is a licensed CPA (inactive) in California.

In connection with his appointment, the Company entered into an employment offer letter with Mr. Prentiss that will govern the terms of his employment with the Company. The employment offer letter provides that Mr. Prentiss will receive an annual base salary of \$460,000 and will be eligible to receive an annual performance bonus with a target bonus percentage equal to 50% of his base salary. In addition, Mr. Prentiss will be eligible to receive relocation assistance benefits through the Company's relocation assistance program. The employment offer letter also provides that Mr. Prentiss will be eligible to participate in the Company's 2018 Equity Incentive Plan (the "2018 EIP"), and will be entitled to receive (a) an equity award of 103,600 restricted stock units ("RSUs"), which will vest 1/3 on each of the second, third and fourth anniversaries of the vesting commencement date, subject to the terms of the 2018 EIP and related RSU award agreement, and (b) at the Company's next annual grant cycle for its executive officers in May 2024, an equity award at the same level as its other Executive Vice Presidents, expected to be comprised 55% of performance-based RSUs and 45% of time-based RSUs. In addition, on or shortly after the Effective Time, Mr. Prentiss will enter into a Change of Control Agreement in substantially the form filed with the Securities and Exchange Commission ("SEC") on April 7, 2017 as Exhibit 99.1 to the Company's Current Report on Form 8-K, which will provide that if Mr. Prentiss's employment is subject to an involuntary termination within two years following a change in control, he will be entitled to receive continued payment of base salary for 18 months, payment of his group health insurance premiums for up to 18 months, a prorated annual performance bonus and full accelerated vesting of any unvested equity awards. Mr. Prentiss may also be entitled to receive tax gross up payments in the event any payments made in connection with a change in control are subject to the excise taxes imposed by Sections 280G and 4999 of the Internal Revenue Code.

Mr. Prentiss will also enter into an indemnity agreement with the Company in the form previously filed with the SEC as Exhibit 10.1 to the Company's Registration Statement on Form S-1, originally filed with the SEC on April 30, 2004, as amended.

Item 9.01 Financial Statements and Exhibits.

(d)

| Exhibit No. | Description of Document |
|--------------|--|
| Exhibit 10.1 | Offer Letter, dated March 25, 2024, between MannKind Corporation and Chris Prentiss. |
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MannKind Corporation

Date: March 26, 2024

By: /s/ David Thomson

David Thomson, Ph.D., J.D. Executive Vice President, General Counsel and

Secretary